Scientists provide an overview of the potential response prediction biomarkers and synergistic combinations studied in the preclinical and clinical stages, which may expand the population of patients with prostate cancer who may benefit from PARP inhibitors.
[Acta Pharmacologica Sinica]
6807162 EF4PAKGX items 1 apa default asc 1
Scientists interrogated both proteomics and transcriptomic alterations stimulated in AR antagonist/anti-androgen treated androgen-dependent cell model in comparison with androgen-independent/castration-resistant cell model.
6807162 ZG7KUAMM items 1 apa default asc 1
Scientists studied prostate cancer contractility as a function of microenvironment stiffness and metastatic potential.
Investigators recapitulated the tumor cells – macrophages interactions in cell culture using prostate cancer cell lines.
6807162 CSWQKC2F items 1 apa default asc 1
Osmulski, P. A., Cunsolo, A., Qian, Y., Chen, M., Lin, C.-L., Hung, C.-N., Mahalingam, D., Kirma, N., Chen, C.-L., Taverna, J., Liss, M., Thompson, I. M., Huang, T. H., & Gaczynska, M. (2021). Macrophages Support the Aggressive Mechanical Phenotype of Circulating Tumor Cells in Prostate Cancer. Biophysical Journal, 120(3), 64a–65a. https://doi.org/10.1016/j.bpj.2020.11.619 Cite
Researchers produced gallium-66 suitable for radiolabeling, and investigated the imaging properties of gallium-66 labeled gastrin-releasing peptide receptor (GRPR)-antagonist NOTA-PEG2-RM26 for later-time point PET-imaging of GRPR expression. In vitro, [66Ga]Ga-NOTA-PEG2-RM26 was characterized in GRPR-expressing PC-3 prostate cancer cells.
6807162 XC55ATLA items 1 apa default asc 1
Researchers explored whether the anti-prostate cancer activity of the ARATs abiraterone and enzalutamide was enhanced by metformin.
6807162 ZISN899W items 1 apa default asc 1
Xie, Y., Wang, L., Khan, M. A., Hamburger, A. W., Guang, W., Passaniti, A., Munir, K., Ross, D. D., Dean, M., & Hussain, A. (2021). Metformin and Androgen Receptor-Axis-Targeted (ARAT) Agents Induce Two PARP-1-Dependent Cell Death Pathways in Androgen-Sensitive Human Prostate Cancer Cells. Cancers, 13(4), 633. https://doi.org/10.3390/cancers13040633 Cite
Investigators indicated that V-ATPase dysregulation was directly linked to both hormone responsive and castrate-resistant prostate cancer via impact on androgen receptor function.
[Molecular Cancer Therapeutics]
6807162 ME7HXDYN items 1 apa default asc 1
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase III TITAN study, which demonstrated the continued statistically significant benefit of the addition of apalutamide to androgen deprivation therapy (ADT) in overall survival in patients with metastatic castration-sensitive prostate cancer, regardless of extent of disease, when compared to placebo plus ADT.
[Janssen Pharmaceutical Companies of Johnson & Johnson]
6807162 nan items 1 apa default asc 1
Scientists identified potential early driver genes responsible for castration-resistant prostate cancer development.
[Prostate Cancer and Prostatic Diseases]
6807162 BYKDUHJB items 1 apa default asc 1
He, H., Hao, J., Dong, X., Wang, Y., Xue, H., Qu, S., Choi, S. Y. C., Ci, X., Wang, Y., Wu, R., Shi, M., Zhao, X., Collins, C., Lin, D., & Wang, Y. (2021). ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development. Prostate Cancer and Prostatic Diseases, 1–11. https://doi.org/10.1038/s41391-021-00322-7 Cite
The authors summarize the current knowledge on androgen indifferent prostate cancer (AIPC) variants, including the current understanding of the clinical, morphologic, and molecular features as well as current therapeutic approaches. They also explore emerging therapies and biomarkers aimed at improving outcomes for men with AIPC.
[Prostate Cancer and Prostatic Diseases]
A systematical analysis of long-chain fatty acyl-CoA synthetases (ACSLs) levels and the amount of fatty acyl-CoAs illustrated that ACSL1 were significantly associated with the levels of a broad spectrum of fatty acyl-CoAs, and were elevated in human prostate tumors.
6807162 5KUSANN4 items 1 apa default asc 1
Ma, Y., Zha, J., Yang, X., Li, Q., Zhang, Q., Yin, A., Beharry, Z., Huang, H., Huang, J., Bartlett, M., Ye, K., Yin, H., & Cai, H. (2021). Long-chain fatty acyl-CoA synthetase 1 promotes prostate cancer progression by elevation of lipogenesis and fatty acid beta-oxidation. Oncogene, 1–15. https://doi.org/10.1038/s41388-021-01667-y Cite